- Conditions
- New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
- Interventions
- Anakinra, Tocilizumab, Standard medical treatment
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–40
of 40
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Foot, Pressure Ulcer, Surgical Wound Dehiscence, Vasculitis, Skin Ulcer, Leg Ulcer, Pyoderma, Peripheral Arterial Disease, Lymphedema, Surgical Complication, Venous Leg Ulcers (VLUs), Calciphylaxis, Sickle Cell Ulcer, Pressure Ulcer (PU), Diabetic Foot Ulcers (DFUs), Pressure Injury, Arterial Ulcers, Soft Tissue Radionecrosis (STRN), Traumatic Wounds, Chronic Ulcer
- Interventions
- Usual care
- Other
- Lead sponsor
- U.S. Wound Registry
- Other
- Eligibility
- Not listed
- Enrollment
- 300,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2030
- U.S. locations
- 1
- States / cities
- The Woodlands, Texas
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Survey Administration
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Months to 37 Years
- Enrollment
- 549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Kingman, Arizona • Oakland, California + 50 more
- Conditions
- Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
- Interventions
- High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
- Conditions
- Retroperitoneal Liposarcoma, Soft Tissue Sarcoma
- Interventions
- Biospecimen sample collection during standard-of-care surgery
- Other
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Sclerosis
- Interventions
- Natalizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Idiopathic Venous Thromboembolism
- Interventions
- Application of the"Men continue and HER DOO2" rule
- Other
- Lead sponsor
- Ottawa Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,779 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 3
- States / cities
- Santa Monica, California • Rockport, Maine • Durham, North Carolina
- Conditions
- Colon Carcinoma, Colorectal Carcinoma, Rectal Carcinoma, Stage I Colon Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Interventions
- Zanidatamab, Resection, Patient Observation, Echocardiography Test, Multigated Acquisition Scan, Endoscopic Procedure, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection, Biopsy Procedure, Digital Rectal Examination, Electronic Health Record Review
- Biological · Procedure · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Decatur, Georgia
- Conditions
- Coronary Artery Disease
- Interventions
- Not listed
- Lead sponsor
- HeartFlow, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Redwood City, California • Stanford, California • Durham, North Carolina
- Conditions
- Neoplasms
- Interventions
- TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more
- Conditions
- HIV
- Interventions
- rilpivirine/cabotegravir
- Drug
- Lead sponsor
- Whitman-Walker Institute
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Spinal Muscular Atrophy, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type 3
- Interventions
- Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care, One time survey
- Drug · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Baltimore, Maryland + 7 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Radiotherapy, LHRHa, Apalutamide
- Radiation · Drug
- Lead sponsor
- Janssen Pharmaceutica N.V., Belgium
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2031
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more
- Conditions
- Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
- Interventions
- Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
- Other · Drug
- Lead sponsor
- University Health Network, Toronto
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Los Angeles, California • San Diego, California + 20 more
- Conditions
- Myelodysplastic Syndromes, Adult
- Interventions
- Observational
- Other
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8
- Interventions
- Zidovudine, Liposomal Doxorubicin, Valganiclovir, Rituximab, Standard Therapies, Cohort 1
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland